- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00405067
The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia
A Randomized, Double-Blind, Active Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination BMS-201038 (AEGR-733) and Ezetimibe vs. Monotherapy in Subjects With Moderate Hypercholesterolemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects will participate in this study for approximately 14-17 weeks. This study has 2 periods: 1) a 1-2-week screening period with 2 visits where baseline cholesterol and other characteristics will be evaluated to determine study eligibility. This period also includes a 4-week washout for patients on prior lipid-lowering therapies; and 2) a 12-week treatment period with interim visits at weeks 4 and 8.
85 subjects were randomized into one of 3 treatment arms with equal probability. In treatment arm 1, subjects will receive BMS-201038 (AEGR-733) 5 mg plus ezetimibe placebo. In treatment arm 2, subjects will receive BMS-201038 (AEGR-733) placebo plus 10 mg of ezetimibe. In treatment arm 3, subjects will receive BMS-201038 (AEGR-733) 5 mg plus ezetimibe 10 mg. After 4 weeks of treatment, subjects in arms 1 and 3 will be force-titrated to BMS-201038 (AEGR-733) 7.5 mg. After another 4 weeks of treatment, subjects in arms 1 and 3 will then be force-titrated to BMS-201038 (AEGR-733) 10 mg for 4 more additional weeks of treatment. Subjects in arm 2 will continue to receive BMS-201038 (AEGR-733) matching placebo for the entire 12 weeks of treatment. Subjects randomized to ezetimibe 10 mg in arms 2 and 3 and ezetimibe placebo in arm 1 will remain on these doses for the entire 12-week treatment period.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New Jersey
-
Princeton, New Jersey, United States, 08540-6242
- Pharmanet, Inc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women between the ages of 18 and 70 years .
- For subjects with 0 to 1 risk factor (cigarette smoking, hypertension (BP > 140/90 or on antihypertensive medication), low HDL (<40mg/dl), family history of premature CHD (CHD in male first degree relative <55 years; CHD in female first degree relative <65 years), age (men> 45 years; women > 55 years): Baseline mean LDL-C must be >160 and <250 mg/dl as determined by the arithmetic mean of measures taken at visit 1 and 2. Fasting mean TGs should be <400 mg/dl.
- For subjects with 2 or more risk factors (cigarette smoking, hypertension (BP > 140/90 or on antihypertensive medication), low HDL (<40mg/dl), family history of premature CHD (CHD in male first degree relative <55 years; CHD in female first degree relative <65 years), age (men> 45 years; women > 55 years) or prior stable CHD: Baseline mean LDL-C must be >130 and <250 mg/dl as determined by the arithmetic mean of measures taken at visit 1 and 2. Fasting mean TGs should be <400 mg/dl.
- Able to understand and willing to comply with all study requirements, particularly the study drug regimen.
- Able to understand and willing to sign the Informed Consent Form.
Exclusion Criteria:
- Women who are pregnant or lactating or who are planning to become pregnant or women of child bearing potential who have not successfully been using acceptable contraceptive methods over the previous 3 months (e.g. intrauterine device and barrier method plus spermicide).
- Uncontrolled hypertension defined as: systolic blood pressure > 180 mmHg, diastolic blood pressure > 95 mmHg
- History of chronic renal insufficiency (serum creatinine >2.5 mg/dL)
- History of liver disease or transaminases above 1.5 X ULN at screening
- Any major surgical procedure occurring less than 3 months prior to the screening visit
- Cardiac insufficiency defined by the NYHA classification as functional Class II-Class IV
- History of a malignancy (other than basal cell or squamous cell carcinoma of the skin that has been removed) within the previous 5 years
- Participation in an investigational drug study within 6 weeks prior to the screening visit.
- Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.
- Regular alcohol use > 1 drink per day
- Regular consumers of grapefruit juice, or currently taking medications known to be metabolized by CYP 3A4 (cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, and nefazodone)
- Other lipid-lowering medications (washouts will be permitted)
- Acute CVD (CVD event within the previous 6 months)
- Diabetes Mellitus
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent Change in LDL-C at 12 Weeks Therapy Compared to Baseline Between Treatments
Time Frame: Baseline and 12 weeks of treatment
|
Baseline and 12 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percent of Change at 12 Weeks Therapy Compared to Baseline Between Treatments for the Following Parameters: Total Cholesterol (TC)
Time Frame: Baseline and 12 weeks of treatment
|
Baseline and 12 weeks of treatment
|
Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at 12 Weeks as Compared to Baseline.
Time Frame: Baseline and 12 weeks of treatment
|
Baseline and 12 weeks of treatment
|
Percent Change in Tryglycerides (TGs) at 12 Weeks Compared to Baseline
Time Frame: Baseline and 12 weeks of treatment
|
Baseline and 12 weeks of treatment
|
Percent Change in HDL-C at 12 Weeks Compared to Baseline
Time Frame: Baseline and 12 weeks of treatment
|
Baseline and 12 weeks of treatment
|
Percent Change in Lipoprotein(a)[Lp(a)]at 12 Weeks as Compared to Baseline
Time Frame: Baseline and 12 weeks of treatment
|
Baseline and 12 weeks of treatment
|
Percent Change in Apolipoprotein A1 (Apo A1) at 12 Weeks as Compared to Baseline
Time Frame: baseline and 12 weeks of treatment
|
baseline and 12 weeks of treatment
|
Percent Change in Apolipoprotein B (Apo B) at 12 Weeks as Compared to Baseline
Time Frame: Baseline and 12 weeks of treatment
|
Baseline and 12 weeks of treatment
|
Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks as Compared to Baseline
Time Frame: Baseline and 12 weeks of treatment
|
Baseline and 12 weeks of treatment
|
Percent Change in Body Weight at 12 Weeks as Compared to Baseline
Time Frame: Baseline and 12 weeks of treatment
|
Baseline and 12 weeks of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Davidson, MD, Radiant Research
- Principal Investigator: Jackson Downey, MD, Jacksonville Center for Clinical Research
- Principal Investigator: Paul Grena, MD, Cardiology Consultants of Philadelphia
- Principal Investigator: Barry Lubin, MD, Hampton Roads Center for Clinical Research
- Principal Investigator: James McKenney, Pharm D, National Clinical Research
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AEGR-733-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineUnknownPrimary HypercholesterolemiaUnited States
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
Boryung Pharmaceutical Co., LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Ahn-Gook Pharmaceuticals Co.,LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
Clinical Trials on Ezetimibe
-
Organon and CoCompletedCoronary Disease | Hypercholesterolemia
-
Organon and CoCompletedCoronary Disease | Hypercholesterolemia
-
Organon and CoCompletedCoronary Disease | Hypercholesterolemia
-
Organon and CoCompletedCoronary Disease | Hypercholesterolemia
-
Bronx VA Medical CenterCompletedHypercholesterolemiaUnited States
-
Cao YuRecruiting
-
The Affiliated Hospital of Qingdao UniversityCompleted
-
Karo Bio ABCompleted
-
Korea UniversityWithdrawn
-
GlaxoSmithKlineCompleted